Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.5700 (-1.65%) ($6.5700 - $6.5700) on Tue. Sep. 14, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.7% (three month average) | RSI | 62 | Latest Price | $6.5700(-1.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2.2% a day on average for past five trading days. | Weekly Trend | AUTL advances 1.1% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(53%) ARKG(48%) ARKK(48%) IBUY(48%) IWO(48%) | Factors Impacting AUTL price | AUTL will decline at least -1.85% in a week (0% probabilities). VIXM(-33%) VXX(-29%) SHY(-21%) TLT(-18%) XLU(-15%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.85% (StdDev 3.7%) | Hourly BBV | -2.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.63 | 5 Day Moving Average | $6.83(-3.81%) | 10 Day Moving Average | $7(-6.14%) | 20 Day Moving Average | $6.63(-0.9%) | To recent high | -17.3% | To recent low | 23.6% | Market Cap | $343m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |